Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Medtronic
McKesson

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR VYXEOS


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vyxeos

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02286726 ↗ CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Completed Celator Pharmaceuticals Phase 2 2015-05-04 This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02286726 ↗ CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 2 2015-05-04 This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02286726 ↗ CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia Completed M.D. Anderson Cancer Center Phase 2 2015-05-04 This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02533115 ↗ EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML Approved for marketing Celator Pharmaceuticals 1969-12-31 This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.
NCT02533115 ↗ EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML Approved for marketing Jazz Pharmaceuticals 1969-12-31 This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.
NCT02642965 ↗ Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2016-04-25 This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back after treatment (relapsed) or is not responding to treatment (is refractory). Liposome-encapsulated daunorubicin-cytarabine is made up of two chemotherapy drugs, cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving liposome-encapsulated daunorubicin-cytarabine followed by fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common effect of other chemotherapy treatments for acute myeloid leukemia.
NCT02642965 ↗ Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting Children's Oncology Group Phase 1/Phase 2 2016-04-25 This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back after treatment (relapsed) or is not responding to treatment (is refractory). Liposome-encapsulated daunorubicin-cytarabine is made up of two chemotherapy drugs, cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving liposome-encapsulated daunorubicin-cytarabine followed by fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common effect of other chemotherapy treatments for acute myeloid leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vyxeos

Condition Name

Condition Name for Vyxeos
Intervention Trials
Acute Myeloid Leukemia 15
Recurrent Acute Myeloid Leukemia 8
Refractory Acute Myeloid Leukemia 7
Secondary Acute Myeloid Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vyxeos
Intervention Trials
Leukemia 29
Leukemia, Myeloid, Acute 28
Leukemia, Myeloid 26
Myelodysplastic Syndromes 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vyxeos

Trials by Country

Trials by Country for Vyxeos
Location Trials
United States 145
Canada 13
Austria 1
Puerto Rico 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vyxeos
Location Trials
Texas 12
California 8
Washington 7
New York 6
Georgia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vyxeos

Clinical Trial Phase

Clinical Trial Phase for Vyxeos
Clinical Trial Phase Trials
Phase 3 2
Phase 2 16
Phase 1/Phase 2 7
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vyxeos
Clinical Trial Phase Trials
Recruiting 23
Active, not recruiting 3
Not yet recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vyxeos

Sponsor Name

Sponsor Name for Vyxeos
Sponsor Trials
National Cancer Institute (NCI) 17
Jazz Pharmaceuticals 15
M.D. Anderson Cancer Center 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vyxeos
Sponsor Trials
Other 34
Industry 23
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Colorcon
Moodys
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.